Clinical Trials Logo

Clinical Trial Summary

Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04155749
Study type Interventional
Source Gilead Sciences
Contact Arcellx, Inc.
Phone 240-327-0379
Email clinical@arcellx.com
Status Recruiting
Phase Phase 1
Start date November 18, 2019
Completion date November 1, 2035

See also
  Status Clinical Trial Phase
Recruiting NCT06050512 - Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma Phase 1/Phase 2
Completed NCT00932698 - Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma Phase 1
Terminated NCT03683277 - IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic Phase 2
Completed NCT03029234 - Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma Phase 3
Recruiting NCT05530421 - Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Phase 2
Not yet recruiting NCT03559764 - Study of BCMA CAR-T in Multiple Myeloma Early Phase 1
Completed NCT02144038 - Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma Phase 1
Terminated NCT00664378 - Efficacy Study of CYT997 in Multiple Myeloma Phase 2
Terminated NCT03710915 - A Study of HG146 Capsule in Chinese Subjects With Relapsed and Refractory Multiple Myeloma Phase 1
Terminated NCT02223598 - A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies Phase 1
Completed NCT03477643 - Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)
Recruiting NCT03661554 - BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma Early Phase 1